BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LY4066434 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LY4066434\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06607185-2605@assetmemo.bio
DTSTAMP:20261121T005843Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:LY4066434: Phase 1 readout est. (NCT06607185)
DESCRIPTION:LY4066434\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant So
 lid Tumors\nEstimated primary completion: January 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ly4066434#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06607185
URL:https://assetmemo.bio/drug/ly4066434#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
